Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia

Claudie Bosc, Estelle Saland, Aurélie Bousard, Noémie Gadaud, Marie Sabatier, Guillaume Cognet, Thomas Farge, Emeline Boet, Mathilde Gotanègre, Nesrine Aroua, Pierre Luc Mouchel, Nathaniel Polley, Clément Larrue, Eléonore Kaphan, Muriel Picard, Ambrine Sahal, Latifa Jarrou, Marie Tosolini, Florian Rambow, Florence CabonNathalie Nicot, Laura Poillet-Perez, Yujue Wang, Xiaoyang Su, Quentin Fovez, Jérôme Kluza, Rafael José Argüello, Céline Mazzotti, Hervé Avet-Loiseau, François Vergez, Jérôme Tamburini, Jean Jacques Fournié, Ing S. Tiong, Andrew H. Wei, Tony Kaoma, Jean Christophe Marine, Christian Récher, Lucille Stuani, Carine Joffre, Jean Emmanuel Sarry*

*Corresponding author for this work

Research output: Contribution to journal › Article › Research › peer-review

27 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia'. Together they form a unique fingerprint.

Medicine and Dentistry